Active — Not RecruitingPhase 2

A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars

United States16 participantsStarted 2013-10

Plain-language summary

The purpose of this study is to compare the effectiveness of the ePrime fractional radiofrequency system to the 1550-nm fractional photothermolysis system (Fraxel) in the ability to improve acne scar appearance.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects age 18 years and older.
✓. Subjects with bilateral 2x2 cm areas of ice pick and/or boxcar acne scars on their face.
✓. Subjects are in good health.
✓. Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator.

Exclusion criteria

✕. Subjects who have received injectable soft-tissue augmentation materials to the face, or facial ablative resurfacing, within the past 6 months.
✕. Subjects who have received injectable botulinum toxin to the face, or any nonablative laser treatment to the face, within the past 3 months.
✕. Subjects who have local infections, open facial wounds, or other significant local skin disease that would interfere with acne scar treatment with energy devices.
✕. Subjects who are allergic to lidocaine or prilocaine.
✕. Subjects who have a history of abnormal scarring in the treatment area, such as keloid scar formation.
✕. Subjects who have ectropion or or other eyelid disfigurement.
✕. Subjects who have a history of isotretinoin use in the preceding year.
✕. Pregnant or lactating individuals.

What they're measuring

Change in best overall cosmetic appearance (right side or left side better)rated by a blinded dermatologist from baseline to week 16

Timeframe: 1 hour at baseline and week 16

Trial details

NCT IDNCT01976260

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Cicatrix trials